231 related articles for article (PubMed ID: 35442407)
1. The Conundrum of Clinical Trials for the Uveitides: Appropriate Outcome Measures for One Treatment Used in Several Diseases.
Jabs DA; Berkenstock MK; Altaweel MM; Holbrook JT; Sugar EA;
Epidemiol Rev; 2022 Dec; 44(1):2-16. PubMed ID: 35442407
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression for the Uveitides.
Jabs DA
Ophthalmology; 2018 Feb; 125(2):193-202. PubMed ID: 28942074
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A
Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898
[TBL] [Abstract][Full Text] [Related]
5. TACROLIMUS FOR IMMUNOSUPPRESSION IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE, POSTERIOR, OR PANUVEITIDES.
Jabs DA; Thorne JE; Wilkins CS; Habbu KA; Berkenstock MK; Burkholder BM; Chaon BC; Deobhakta A
Retina; 2023 Sep; 43(9):1480-1486. PubMed ID: 37184495
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the Dexamethasone Implant in Lieu of Oral Corticosteroids in Intermediate and Posterior Uveitis Requiring Immunosuppression.
Berkenstock MK; Mir TA; Khan IR; Burkholder BM; Chaon BC; Shifera AS; Thorne JE
Ocul Immunol Inflamm; 2022 Apr; 30(3):741-749. PubMed ID: 33021854
[TBL] [Abstract][Full Text] [Related]
7. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.
Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL
Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
[TBL] [Abstract][Full Text] [Related]
10. Uveitis for the non-ophthalmologist.
Burkholder BM; Jabs DA
BMJ; 2021 Feb; 372():m4979. PubMed ID: 33536186
[TBL] [Abstract][Full Text] [Related]
11. Systemic immunosuppressive therapies for uveitis in developing countries.
Agrawal H; Doan H; Pham B; Khosla A; Babu M; McCluskey P; Nguyen QD; Sangwan V; Reddy S; Sawhney S; Tyagi M
Indian J Ophthalmol; 2020 Sep; 68(9):1852-1862. PubMed ID: 32823402
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.
Squires H; Poku E; Bermejo I; Cooper K; Stevens J; Hamilton J; Wong R; Denniston A; Pearce I; Quhill F
Health Technol Assess; 2017 Nov; 21(68):1-170. PubMed ID: 29183563
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab in Patients with Active Noninfectious Uveitis.
Jaffe GJ; Dick AD; Brézin AP; Nguyen QD; Thorne JE; Kestelyn P; Barisani-Asenbauer T; Franco P; Heiligenhaus A; Scales D; Chu DS; Camez A; Kwatra NV; Song AP; Kron M; Tari S; Suhler EB
N Engl J Med; 2016 Sep; 375(10):932-43. PubMed ID: 27602665
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis.
Lee RW; Greenwood R; Taylor H; Amer R; Biester S; Heissigerova J; Forrester JV; Dick AD
Ophthalmology; 2012 Jun; 119(6):1223-30. PubMed ID: 22381809
[TBL] [Abstract][Full Text] [Related]
17. Defining outcome measures in juvenile idiopathic arthritis associated uveitis by a systematic review analysis: do we need a consensus?
Mastrangelo G; Foeldvari I; Anton J; Simonini G
Pediatr Rheumatol Online J; 2019 Jul; 17(1):40. PubMed ID: 31296236
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
